You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePentamidine
Accession NumberDB00738  (APRD00303, EXPT02625)
TypeSmall Molecule
GroupsApproved
DescriptionAntiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. [PubChem]
Structure
Thumb
Synonyms
1,5-Bis(4-amidinophenoxy)pentane
4,4'-(1,5-Pentanediylbis(oxy))bis-benzenecarboximidamide
4,4'-(Pentamethylenedioxy)dibenzamidine
4,4'-Diamidinodiphenoxypentane
P,P'-(pentamethylenedioxy)dibenzamidine
Pentamidin
Pentamidina
Pentamidindiisetionat
Pentamidine
Pentamidinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NebupentInhalant300 mg/6mLRespiratory (inhalation)APP Pharmaceuticals, LLC2011-02-15Not applicableUs
Pentacarinat 300 Inj Pws 300mg/vialPowder, for solution300 mgIntramuscular; Intravenous; Respiratory (inhalation)Aventis Pharma Inc1989-12-312005-08-01Canada
Pentam 300Injection, powder, lyophilized, for solution300 mg/3mLIntramuscular; IntravenousAPP Pharmaceuticals, LLC2001-01-16Not applicableUs
Pentamidine Isethionate Inj 300mg/vial BPPowder, for solution300 mgIntramuscular; IntravenousDavid Bull Laboratories (Pty) Ltd.1990-12-311998-08-13Canada
Pentamidine Isetionate for Injection, BPPowder, for solution300 mgIntramuscular; IntravenousHospira Healthcare Corporation1998-09-10Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PentacarinatSanofi-Aventis
PentacrinatAbbot
PentamAbbot
Pentamidine isethionateAbbot
PneumopentNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Pentamidine Isethionate
140-64-7
Thumb
  • InChI Key: YBVNFKZSMZGRAD-UHFFFAOYSA-N
  • Monoisotopic Mass: 592.187285723
  • Average Mass: 592.68
DBSALT000967
Categories
UNII673LC5J4LQ
CAS number100-33-4
WeightAverage: 340.4195
Monoisotopic: 340.189926032
Chemical FormulaC19H24N4O2
InChI KeyXDRYMKDFEDOLFX-UHFFFAOYSA-N
InChI
InChI=1S/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23)
IUPAC Name
4-{[5-(4-carbamimidoylphenoxy)pentyl]oxy}benzene-1-carboximidamide
SMILES
NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
Pharmacology
IndicationFor the treatment of pneumonia due to Pneumocystis carinii.
Structured Indications
PharmacodynamicsPentamidine is an antiprotozoal agent. It is an aromatic diamidine, and is known to have activity against Pneumocystis carinii. The exact nature of its antiprotozoal action is unknown. in vitro studies with mammalian tissues and the protozoan Crithidia oncopelti indicate that the drug interferes with nuclear metabolism producing inhibition of the synthesis of DNA, RNA, phospholipids and proteins. Little is known about the drug's pharmacokinetics. The medication is also useful in Leishmaniasis and in prophylaxis against sleeping sickness caused by Trypanosoma brucei gambiense. Hydration before treatment lessens the incidence and severity of side effects, which include liver or kidney dysfunction, hypertension, hypotension, hypoglycemia, hypocalemia, leukopenia, thrombcytopenia, anemia, and allergic reaction. It is generally well-tolerated.
Mechanism of actionThe mode of action of pentamidine is not fully understood. It is thought that the drug interferes with nuclear metabolism producing inhibition of the synthesis of DNA, RNA, phospholipids, and proteins.
TargetKindPharmacological actionActionsOrganismUniProt ID
DNANucleotideunknown
intercalation
Humannot applicabledetails
tRNA (cytosine(38)-C(5))-methyltransferaseProteinunknown
other
HumanO14717 details
Related Articles
AbsorptionAbsorbed poorly through the gastrointestinal tract and is usually administered parenterally.
Volume of distributionNot Available
Protein binding69%
Metabolism

Hepatic.

Route of eliminationNot Available
Half life9.1-13.2 hours
ClearanceNot Available
ToxicitySymptoms of overdose include pain, nausea, anorexia, hypotension, fever, rash, bad taste in mouth, confusion/hallucinations, dizziness, and diarrhea.
Affected organisms
  • Pneumocystis carinii
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Pentamidine.Experimental
AbirateroneThe serum concentration of Pentamidine can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Pentamidine.Approved, Investigational
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Pentamidine.Withdrawn
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Pentamidine.Approved, Vet Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Pentamidine.Experimental
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Pentamidine.Approved
AmantadineAmantadine may increase the QTc-prolonging activities of Pentamidine.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Pentamidine.Approved
AmiodaronePentamidine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Pentamidine.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Amlodipine.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Pentamidine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Pentamidine.Approved, Investigational
AmrinoneThe risk or severity of adverse effects can be increased when Pentamidine is combined with Amrinone.Approved
AnagrelidePentamidine may increase the QTc-prolonging activities of Anagrelide.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
AprepitantThe serum concentration of Pentamidine can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Pentamidine.Approved, Investigational
ArmodafinilThe metabolism of Pentamidine can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxidePentamidine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherPentamidine may increase the QTc-prolonging activities of Artemether.Approved
AsenapinePentamidine may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe metabolism of Pentamidine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Pentamidine.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Azelnidipine.Approved
AzimilideThe risk or severity of adverse effects can be increased when Pentamidine is combined with Azimilide.Investigational
AzithromycinAzithromycin may increase the QTc-prolonging activities of Pentamidine.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Pentamidine.Investigational
BalsalazideBalsalazide may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Barnidipine.Approved
BedaquilinePentamidine may increase the QTc-prolonging activities of Bedaquiline.Approved
BenidipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Benidipine.Approved
BenmoxinBenmoxin may increase the hypoglycemic activities of Pentamidine.Withdrawn
BepridilThe risk or severity of adverse effects can be increased when Pentamidine is combined with Bepridil.Approved, Withdrawn
BetaxololThe metabolism of Pentamidine can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Pentamidine can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Pentamidine can be decreased when combined with Boceprevir.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
BosentanThe serum concentration of Pentamidine can be decreased when it is combined with Bosentan.Approved, Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Pentamidine.Withdrawn
BupropionThe metabolism of Pentamidine can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Pentamidine.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Pentamidine.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Pentamidine.Approved, Investigational
CaffeineThe metabolism of Pentamidine can be decreased when combined with Caffeine.Approved
CaiThe risk or severity of adverse effects can be increased when Pentamidine is combined with Cai.Investigational
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pentamidine.Approved
CarbamazepineThe metabolism of Pentamidine can be increased when combined with Carbamazepine.Approved, Investigational
CaroxazoneCaroxazone may increase the hypoglycemic activities of Pentamidine.Withdrawn
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Pentamidine.Experimental
CelecoxibThe metabolism of Pentamidine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Pentamidine can be increased when it is combined with Ceritinib.Approved
ChloramphenicolThe metabolism of Pentamidine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Pentamidine.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Pentamidine.Approved, Vet Approved
ChlorpropamideChlorpropamide may increase the hypoglycemic activities of Pentamidine.Approved
CholecalciferolThe metabolism of Pentamidine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Pentamidine.Experimental
CilnidipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Cilnidipine.Approved
CimetidineThe metabolism of Pentamidine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Pentamidine can be decreased when combined with Cinacalcet.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Cinnarizine.Approved
CinoxacinCinoxacin may increase the hypoglycemic activities of Pentamidine.Approved, Withdrawn
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Pentamidine.Approved, Investigational, Withdrawn
CitalopramPentamidine may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinPentamidine may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Pentamidine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Clevidipine.Approved
ClobazamThe metabolism of Pentamidine can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineClomipramine may increase the QTc-prolonging activities of Pentamidine.Approved, Vet Approved
ClopidogrelThe metabolism of Pentamidine can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Pentamidine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Pentamidine.Approved
CobicistatThe serum concentration of Pentamidine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Pentamidine can be decreased when combined with Cocaine.Approved, Illicit
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Pentamidine.Approved, Investigational
CrizotinibPentamidine may increase the QTc-prolonging activities of Crizotinib.Approved
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Pentamidine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Pentamidine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Pentamidine can be decreased when it is combined with Dabrafenib.Approved
DapoxetineDapoxetine may increase the hypoglycemic activities of Pentamidine.Investigational
DarifenacinThe metabolism of Pentamidine can be decreased when combined with Darifenacin.Approved, Investigational
DarodipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Darodipine.Experimental
DarunavirThe serum concentration of Pentamidine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Pentamidine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Pentamidine can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Pentamidine.Approved
DelavirdineThe metabolism of Pentamidine can be decreased when combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Pentamidine.Investigational
dersalazinedersalazine may increase the hypoglycemic activities of Pentamidine.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Pentamidine.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Pentamidine.Approved
DesvenlafaxineDesvenlafaxine may increase the hypoglycemic activities of Pentamidine.Approved
DexamethasoneThe serum concentration of Pentamidine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DidanosineDidanosine can cause a decrease in the absorption of Pentamidine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Pentamidine.Approved
DihydroergotamineThe metabolism of Pentamidine can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Pentamidine.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Pentamidine is combined with Diltiazem.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Pentamidine.Approved
DisopyramidePentamidine may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Pentamidine.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Pentamidine.Approved
DolasetronPentamidine may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidonePentamidine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DotarizineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Dotarizine.Investigational
DoxepinDoxepin may increase the QTc-prolonging activities of Pentamidine.Approved
DoxycyclineThe metabolism of Pentamidine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaronePentamidine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Pentamidine.Approved, Vet Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Pentamidine.Approved
DuloxetineThe metabolism of Pentamidine can be decreased when combined with Duloxetine.Approved
EfavirenzThe serum concentration of Pentamidine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Efonidipine.Approved
EliglustatPentamidine may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pentamidine.Approved
EnoxacinEnoxacin may increase the hypoglycemic activities of Pentamidine.Approved
EnzalutamideThe serum concentration of Pentamidine can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Pentamidine is combined with Eperisone.Approved, Investigational
EribulinEribulin may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Pentamidine.Approved, Vet Approved
EscitalopramPentamidine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Pentamidine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Pentamidine can be decreased when combined with Esomeprazole.Approved, Investigational
EtoperidoneEtoperidone may increase the hypoglycemic activities of Pentamidine.Approved
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Pentamidine.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Pentamidine.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Pentamidine.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Pentamidine.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Pentamidine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Fendiline.Withdrawn
FingolimodFingolimod may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
FlecainidePentamidine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FleroxacinFleroxacin may increase the hypoglycemic activities of Pentamidine.Approved
FluconazoleThe metabolism of Pentamidine can be decreased when combined with Fluconazole.Approved
FlumequineFlumequine may increase the hypoglycemic activities of Pentamidine.Withdrawn
FlunarizineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Flunarizine.Approved
FluoxetinePentamidine may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Pentamidine.Approved, Illicit
FlupentixolPentamidine may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluvoxamineThe metabolism of Pentamidine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
FosamprenavirThe metabolism of Pentamidine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Pentamidine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetThe risk or severity of adverse effects can be increased when Pentamidine is combined with Foscarnet.Approved
FosphenytoinThe serum concentration of Pentamidine can be decreased when it is combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypoglycemic activities of Pentamidine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Pentamidine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Pentamidine is combined with Gabapentin.Approved, Investigational
Gadobenic acidPentamidine may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Pentamidine.Approved
GallopamilThe risk or severity of adverse effects can be increased when Pentamidine is combined with Gallopamil.Investigational
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Pentamidine.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
GemfibrozilThe metabolism of Pentamidine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinPentamidine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Pentamidine.Withdrawn
GliclazidePentamidine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideGlimepiride may increase the hypoglycemic activities of Pentamidine.Approved
GlipizidePentamidine may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Pentamidine.Approved
GlyburidePentamidine may increase the hypoglycemic activities of Glyburide.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Pentamidine.Approved
GranisetronPentamidine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrepafloxacinGrepafloxacin may increase the hypoglycemic activities of Pentamidine.Withdrawn
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Pentamidine.Investigational
HaloperidolHaloperidol may increase the QTc-prolonging activities of Pentamidine.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Pentamidine.Approved
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Pentamidine.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Pentamidine.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
IbutilidePentamidine may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Pentamidine can be increased when it is combined with Idelalisib.Approved
IloperidonePentamidine may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Pentamidine can be decreased when combined with Imatinib.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Pentamidine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Pentamidine.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Pentamidine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Pentamidine.Approved
IndinavirThe metabolism of Pentamidine can be decreased when combined with Indinavir.Approved
Insulin AspartPentamidine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirPentamidine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Pentamidine.Approved
Insulin GlulisinePentamidine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanInsulin Human may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Pentamidine.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Pentamidine.Approved
IproclozideIproclozide may increase the hypoglycemic activities of Pentamidine.Withdrawn
IproniazidIproniazid may increase the hypoglycemic activities of Pentamidine.Withdrawn
IrbesartanThe metabolism of Pentamidine can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Pentamidine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Pentamidine.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Pentamidine.Approved, Vet Approved
IsoniazidThe metabolism of Pentamidine can be decreased when combined with Isoniazid.Approved
IsradipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Isradipine.Approved
ItraconazoleThe metabolism of Pentamidine can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Pentamidine.Approved
IvacaftorThe serum concentration of Pentamidine can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Pentamidine can be decreased when combined with Ketoconazole.Approved, Investigational
LacidipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Lacidipine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Lamotrigine.Approved, Investigational
LanreotidePentamidine may increase the hypoglycemic activities of Lanreotide.Approved
LapatinibLapatinib may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
LenvatinibPentamidine may increase the QTc-prolonging activities of Lenvatinib.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Lercanidipine.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
LevofloxacinPentamidine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Pentamidine.Approved
LidocaineThe metabolism of Pentamidine can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Pentamidine.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Pentamidine.Approved
LithiumLithium may increase the QTc-prolonging activities of Pentamidine.Approved
LomefloxacinLomefloxacin may increase the hypoglycemic activities of Pentamidine.Approved
LopinavirPentamidine may increase the QTc-prolonging activities of Lopinavir.Approved
LorcaserinThe metabolism of Pentamidine can be decreased when combined with Lorcaserin.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Pentamidine.Approved
LovastatinThe metabolism of Pentamidine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Pentamidine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Pentamidine can be increased when it is combined with Lumacaftor.Approved
LumefantrinePentamidine may increase the QTc-prolonging activities of Lumefantrine.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Pentamidine is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Manidipine.Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Pentamidine.Approved
MebanazineMebanazine may increase the hypoglycemic activities of Pentamidine.Withdrawn
MecaserminPentamidine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MefloquineMefloquine may increase the QTc-prolonging activities of Pentamidine.Approved
MequitazinePentamidine may increase the arrhythmogenic activities of Mequitazine.Approved
MesalazineMesalazine may increase the hypoglycemic activities of Pentamidine.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Pentamidine.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Pentamidine.Approved
MethotrimeprazineThe metabolism of Pentamidine can be decreased when combined with Methotrimeprazine.Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Pentamidine.Investigational
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Pentamidine.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
MetoprololThe metabolism of Pentamidine can be decreased when combined with Metoprolol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Pentamidine.Approved
MexiletineThe metabolism of Pentamidine can be decreased when combined with Mexiletine.Approved
MibefradilThe risk or severity of adverse effects can be increased when Pentamidine is combined with Mibefradil.Withdrawn
MifepristoneMifepristone may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Pentamidine.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Pentamidine.Approved
MilnacipranMilnacipran may increase the hypoglycemic activities of Pentamidine.Approved
MinaprineMinaprine may increase the hypoglycemic activities of Pentamidine.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Pentamidine.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Pentamidine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Pentamidine.Approved, Investigational
MitotaneThe serum concentration of Pentamidine can be decreased when it is combined with Mitotane.Approved
MoclobemideMoclobemide may increase the hypoglycemic activities of Pentamidine.Approved
ModafinilThe serum concentration of Pentamidine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Pentamidine.Approved
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
NafcillinThe serum concentration of Pentamidine can be decreased when it is combined with Nafcillin.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Pentamidine is combined with Naftopidil.Investigational
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Pentamidine.Approved
NateglinideNateglinide may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
NCX 4016NCX 4016 may increase the hypoglycemic activities of Pentamidine.Investigational
NefazodoneThe metabolism of Pentamidine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Pentamidine can be decreased when combined with Nelfinavir.Approved
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Pentamidine.Investigational
NetupitantThe serum concentration of Pentamidine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Pentamidine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypoglycemic activities of Pentamidine.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nicardipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Niguldipine.Experimental
NilotinibPentamidine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NiludipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nitrendipine.Approved
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Pentamidine.Investigational
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Pentamidine.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Pentamidine.Approved
OctamoxinOctamoxin may increase the hypoglycemic activities of Pentamidine.Withdrawn
OctreotideOctreotide may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
OfloxacinPentamidine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
OlaparibThe metabolism of Pentamidine can be decreased when combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Pentamidine.Approved
OlsalazineOlsalazine may increase the hypoglycemic activities of Pentamidine.Approved
OmeprazoleThe metabolism of Pentamidine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronPentamidine may increase the QTc-prolonging activities of Ondansetron.Approved
OsimertinibThe serum concentration of Pentamidine can be increased when it is combined with Osimertinib.Approved
OxandroloneOxandrolone may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
OxymetholoneOxymetholone may increase the hypoglycemic activities of Pentamidine.Approved, Illicit
OxytocinOxytocin may increase the QTc-prolonging activities of Pentamidine.Approved, Vet Approved
PalbociclibThe serum concentration of Pentamidine can be increased when it is combined with Palbociclib.Approved
PaliperidonePentamidine may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatThe serum concentration of Pentamidine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Pentamidine can be decreased when combined with Pantoprazole.Approved
PargylinePargyline may increase the hypoglycemic activities of Pentamidine.Approved
ParoxetineThe metabolism of Pentamidine can be decreased when combined with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Pentamidine.Approved
PazopanibPentamidine may increase the QTc-prolonging activities of Pazopanib.Approved
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Pentamidine.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Pentamidine.Approved
Peginterferon alfa-2bThe serum concentration of Pentamidine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Pentamidine.Approved
PentobarbitalThe metabolism of Pentamidine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Pentamidine.Approved
PerhexilineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Perhexiline.Approved
PhenelzinePhenelzine may increase the hypoglycemic activities of Pentamidine.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Pentamidine.Approved, Withdrawn
PheniprazinePheniprazine may increase the hypoglycemic activities of Pentamidine.Withdrawn
PhenobarbitalThe metabolism of Pentamidine can be increased when combined with Phenobarbital.Approved
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Pentamidine.Withdrawn
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Pentamidine.Approved, Vet Approved
PimozidePentamidine may increase the arrhythmogenic activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Pentamidine is combined with Pinaverium.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Pentamidine.Approved, Investigational
PirlindolePirlindole may increase the hypoglycemic activities of Pentamidine.Approved
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Pentamidine.Withdrawn
PosaconazoleThe metabolism of Pentamidine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Pentamidine.Approved, Investigational
PregabalinThe risk or severity of adverse effects can be increased when Pentamidine is combined with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Prenylamine.Withdrawn
PrimaquinePentamidine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Pentamidine can be increased when combined with Primidone.Approved, Vet Approved
ProcainamidePentamidine may increase the QTc-prolonging activities of Procainamide.Approved
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Pentamidine.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Pentamidine.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Pentamidine.Approved
PropafenonePentamidine may increase the QTc-prolonging activities of Propafenone.Approved
PropofolPropofol may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational, Vet Approved
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Pentamidine.Approved
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Pentamidine.Investigational
QuetiapinePentamidine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Pentamidine.Approved
QuininePentamidine may increase the QTc-prolonging activities of Quinine.Approved
RabeprazoleThe metabolism of Pentamidine can be decreased when combined with Rabeprazole.Approved, Investigational
RanolazineThe metabolism of Ranolazine can be decreased when combined with Pentamidine.Approved, Investigational
RasagilineRasagiline may increase the hypoglycemic activities of Pentamidine.Approved
RepaglinidePentamidine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RifabutinThe metabolism of Pentamidine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Pentamidine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Pentamidine can be increased when combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Pentamidine.Approved
RisedronateThe risk or severity of adverse effects can be increased when Pentamidine is combined with Risedronate.Approved, Investigational
RisperidoneRisperidone may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
RitonavirThe metabolism of Pentamidine can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Pentamidine can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Pentamidine can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Pentamidine.Approved, Investigational
RosoxacinRosoxacin may increase the hypoglycemic activities of Pentamidine.Approved
SafrazineSafrazine may increase the hypoglycemic activities of Pentamidine.Withdrawn
SalbutamolSalbutamol may increase the QTc-prolonging activities of Pentamidine.Approved, Vet Approved
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Pentamidine.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Pentamidine.Approved
SaquinavirPentamidine may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Pentamidine.Approved
SecobarbitalThe metabolism of Pentamidine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypoglycemic activities of Pentamidine.Approved, Investigational, Vet Approved
SertralineSertraline may increase the QTc-prolonging activities of Pentamidine.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Pentamidine.Approved, Vet Approved
SildenafilThe metabolism of Pentamidine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Pentamidine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Pentamidine can be increased when it is combined with Simeprevir.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Pentamidine.Approved, Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Pentamidine.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
SotalolPentamidine may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Pentamidine.Approved
St. John's WortThe serum concentration of Pentamidine can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololStanozolol may increase the hypoglycemic activities of Pentamidine.Approved, Vet Approved
StiripentolThe serum concentration of Pentamidine can be increased when it is combined with Stiripentol.Approved
SucralfateSucralfate can cause a decrease in the absorption of Pentamidine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulfadiazineSulfadiazine may increase the hypoglycemic activities of Pentamidine.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Pentamidine.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Pentamidine.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Pentamidine.Approved, Investigational
SunitinibThe metabolism of Sunitinib can be decreased when combined with Pentamidine.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Pentamidine.Approved, Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Pentamidine.Approved
TelaprevirThe metabolism of Pentamidine can be decreased when combined with Telaprevir.Approved
TelavancinPentamidine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinPentamidine may increase the QTc-prolonging activities of Telithromycin.Approved
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Pentamidine.Withdrawn
TenofovirThe metabolism of Pentamidine can be decreased when combined with Tenofovir.Approved, Investigational
TerbinafineThe metabolism of Pentamidine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Pentamidine.Approved
TeriflunomideThe serum concentration of Pentamidine can be decreased when it is combined with Teriflunomide.Approved
TestosteroneTestosterone may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
TetrabenazinePentamidine may increase the QTc-prolonging activities of Tetrabenazine.Approved
TheophyllineThe metabolism of Pentamidine can be decreased when combined with Theophylline.Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Pentamidine.Investigational
ThioridazinePentamidine may increase the QTc-prolonging activities of Thioridazine.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Pentamidine.Approved
TiclopidineThe metabolism of Pentamidine can be decreased when combined with Ticlopidine.Approved
TipranavirThe metabolism of Pentamidine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Pentamidine.Approved
TocilizumabThe serum concentration of Pentamidine can be decreased when it is combined with Tocilizumab.Approved
TolazamidePentamidine may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamidePentamidine may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Pentamidine is combined with Tolfenamic Acid.Approved
ToloxatoneToloxatone may increase the hypoglycemic activities of Pentamidine.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
TopiramateThe metabolism of Pentamidine can be decreased when combined with Topiramate.Approved
ToremifenePentamidine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Pentamidine is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Pentamidine.Experimental
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Pentamidine.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Pentamidine.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Pentamidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Pentamidine.Approved, Vet Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Pentamidine.Withdrawn
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Pentamidine.Approved, Withdrawn
VandetanibPentamidine may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Pentamidine.Approved
VemurafenibThe serum concentration of Pentamidine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Pentamidine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Pentamidine is combined with Verapamil.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Pentamidine.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Pentamidine.Approved, Investigational
VinpocetineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Vinpocetine.Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Pentamidine.Approved, Investigational
VoriconazoleThe metabolism of Pentamidine can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
XylometazolineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Xylometazoline.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Pentamidine is combined with Ziconotide.Approved
ZimelidineZimelidine may increase the hypoglycemic activities of Pentamidine.Withdrawn
ZiprasidonePentamidine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Pentamidine.Approved
ZuclopenthixolPentamidine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Nguewa PA, Fuertes MA, Cepeda V, Iborra S, Carrion J, Valladares B, Alonso C, Perez JM: Pentamidine is an antiparasitic and apoptotic drug that selectively modifies ubiquitin. Chem Biodivers. 2005 Oct;2(10):1387-400. [PubMed:17191940 ]
External Links
ATC CodesP01CX01
AHFS Codes
  • 08:30.92
PDB Entries
FDA labelNot Available
MSDSDownload (50.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9416
Blood Brain Barrier+0.9133
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.5352
P-glycoprotein inhibitor INon-inhibitor0.8571
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterInhibitor0.6653
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.7339
CYP450 1A2 substrateNon-inhibitor0.5272
CYP450 2C9 inhibitorNon-inhibitor0.7439
CYP450 2D6 inhibitorNon-inhibitor0.7676
CYP450 2C19 inhibitorNon-inhibitor0.6581
CYP450 3A4 inhibitorNon-inhibitor0.8661
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5621
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8395
BiodegradationNot ready biodegradable0.9818
Rat acute toxicity2.2925 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7428
hERG inhibition (predictor II)Non-inhibitor0.7711
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • App pharmaceuticals llc
  • Armour pharmaceutical co
  • Baxter healthcare corp anesthesia and critical care
  • Hospira inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
InhalantRespiratory (inhalation)300 mg/6mL
Powder, for solutionIntramuscular; Intravenous; Respiratory (inhalation)300 mg
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous300 mg/3mL
Powder, for solutionIntramuscular; Intravenous300 mg
Prices
Unit descriptionCostUnit
Nebupent 300 mg inhal powder122.84USD each
Pentam 300 vial94.8USD vial
Pentamidine 300 mg vial45.31USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point186.0 °C (decomposes)Not Available
water solubilityCompleteNot Available
logP4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0236 mg/mLALOGPS
logP1.32ALOGPS
logP2.32ChemAxon
logS-4.2ALOGPS
pKa (Strongest Basic)12.13ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area118.2 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity120.53 m3·mol-1ChemAxon
Polarizability38.85 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenol ethers
Direct ParentPhenol ethers
Alternative Parents
Substituents
  • Phenol ether
  • Alkyl aryl ether
  • Carboximidamide
  • Ether
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
unknown
Actions
intercalation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Shankar SM, Nania JJ: Management of Pneumocystis jiroveci pneumonia in children receiving chemotherapy. Paediatr Drugs. 2007;9(5):301-9. [PubMed:17927302 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Trna methyltransferase activity
Specific Function:
Specifically methylates cytosine 38 in the anticodon loop of tRNA(Asp).
Gene Name:
TRDMT1
Uniprot ID:
O14717
Molecular Weight:
44596.17 Da
References
  1. Sun T, Zhang Y: Pentamidine binds to tRNA through non-specific hydrophobic interactions and inhibits aminoacylation and translation. Nucleic Acids Res. 2008 Mar;36(5):1654-64. doi: 10.1093/nar/gkm1180. Epub 2008 Feb 7. [PubMed:18263620 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Afrin LB, Afrin JB: Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration. Clin Transplant. 2011 May-Jun;25(3):E271-5. doi: 10.1111/j.1399-0012.2011.01399.x. Epub 2011 Feb 7. [PubMed:21299635 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM: Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42. Epub 2003 Aug 12. [PubMed:12920490 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM: Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42. Epub 2003 Aug 12. [PubMed:12920490 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM: Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42. Epub 2003 Aug 12. [PubMed:12920490 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Leukotriene-b4 20-monooxygenase activity
Specific Function:
Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE).
Gene Name:
CYP4A11
Uniprot ID:
Q02928
Molecular Weight:
59347.31 Da
References
  1. Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM: Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42. Epub 2003 Aug 12. [PubMed:12920490 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:46